As of Sep 30
| 0.00 / 0.00%|
The 2 analysts offering 12-month price forecasts for ContraVir Pharmaceuticals Inc have a median target of 4.50, with a high estimate of 5.00 and a low estimate of 4.00. The median estimate represents a +320.56% increase from the last price of 1.07.
The current consensus among 2 polled investment analysts is to Buy stock in ContraVir Pharmaceuticals Inc. This rating has held steady since September, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.